Nemaura Medical (OTC:NMRD) touted precision data today from the on-going European clinical trial program of its non-invasive, needle-free glucose monitoring system, sugarBeat.
The study included 16 patients with Type I and Type II diabetes. The participants wore two sugarBeat skin-patches simultaneously over 3 days for up to 14 hours each day.
The trial showed that more than 80% of the data between the two skin-patches at each time point were within 8% of each other.
Results from the precision trial provide concrete validation of the sugarBeat system, the company said.
“The precision study for sugarBeat has exceeded our expectations and is a significant milestone towards commercial launch,” CEO Faz Chowdhury said in prepared remarks.
Nemaura’s on-going clinical trial program in Europe is slated to finish later this month and the company said it hopes to launch sugarBeat in the U.K. in early 2018.
Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.